Join Dr. Donia Bouzid for an interactive webinar on the clinical utility of dry swabs for respiratory testing in a hospital in Paris.
Date and time: September 23, 2021 at 14:00 CET/15:00 Helsinki time
Title: The clinical outcomes of using dry swabs for respiratory syndromic testing: Experience from a hospital in Paris
Speaker: Donia Bouzid, M.D., Ph.D., AP-HP, Bichat Claude-Bernard Hospital, Emergency Department, Paris, France
Patients with infectious illnesses frequently have signs and symptoms that are indicative of a disease but that are not unique enough to clinically distinguish what pathogen is making them ill.
Patients can present with general, non-specific symptoms such as cough, myalgia and headache. The lack of a clear diagnosis results in broad treatment, extensive monitoring and possibly unnecessary interventions.
With syndromic testing, results for multiple pathogens are delivered at once. And compared to traditional methods, it can provide results faster. The benefits of syndromic testing extend through the lab, hospital and to the patients.
A patient may have the flu. A cold. Or they may have been exposed to COVID-19. How can you get results that patients need faster? The QIAstat-Dx Respiratory SARS-CoV-2 Panel gets you results for 21 respiratory targets, including SARS-CoV-2, in about an hour.
Before the COVID-19 pandemic, the majority of respiratory illnesses were caused by the seasonal circulation of common pathogens, including influenza virus. Given the uncertainty surrounding respiratory infections in the future, rapid detection and differential of respiratory viruses through syndromic testing will be essential. Read a piece from our medical affairs team on the future of syndromic testing beyond COVID-19.